• Report Description
  • Request ToC
  • Request Methodology

Cytomegalovirus (CMV) is contagious virus commonly spreads through bodily secretions. The virus is related to herpes virus and occurs in all adult population. According to the published article in Havard Health Publishing, around 50-80% population in the US are affected with CMV virus. In addition, virus can transmit from an infected mother to her children through umbilical cord. Center for Disease Control (CDC) data predicts that one out of every 200 babies are born with congenital CMV. The infection is reported in mother during pregnancy. Thus, the rising global burden and the increasing number of children getting infected with CMV demands for an effective diagnostic assay which is further fueling the market growth of CMV assay. However, the CMV infection is still underscored by the lack of awareness among most of the emerging countries which is hindering the growth of the market.

Furthermore, rising prevalence of CMV neonatal infection and CMV retinitis and increasing clinical trial focused on CMV and novel treatment method for diagnosing CMV infection is propelling the market growth. For instance, in February 2021, Takeda’s companies Maribavir an investigational drug TAK-620 for the treatment of CMV entered Phase 3 clinical trial. Such clinical trial studies dedicated on CMV is driving the market growth of CMV assays.

The global cytomegalovirus assay market is expected to grow at a CAGR of around 6.1% over the period of next 5 years.

Get a brochure of this research study Click Here


The market growth cytomegalovirus assay is attributed to key factors such as rising prevalence of CMV globally, rising number of patients undergoing transplantation as these patients have higher risk of contracting the virus, favorable government support to create awareness related to the virus. According to the published article in Virology Biomed central, CMV is the one of the most common cause of congenital infection globally and its prevalence varies between 0.2 % to 2.2 % among infants. It may be symptomatic, but in 85 – 90 % of the cases, it is asymptomatic during birth. The rising prevalence of this virus will demand for an effective diagnostic assay which is further boosting the market growth.

Novel approach for diagnosing CMV is also driving the market growth. For instance, a published article in SpringerLink in 2018, demonstrates the potential role of CMV-specific T-cell measurements in guiding the need for the treatment of asymptomatic CMV infection. These factors are bolstering the demand for cytomegalovirus assay and projected to increase its demand in the near future.


By Assay Type:

  • Serology
  • Cell culture
  • Antigenemia
  • Polymerase Chain Reaction Amplification
  • Immunohistochemistry
  • Nucleic acid sequence-based amplification (NASBA)
  • Hybrid capture assay

By Application:

  • Retinitis
  • Pneumonia
  • Gastrointestinal Ulcers
  • Encephalitis
  • Others

By End user:

  • Diagnostic Laboratories
  • Pathology Labs
  • Life Sciences and Research Labs
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


North America is projected to gain dominance in the cytomegalovirus assay market. The market growth in this region can be attributed to rising number of population suffering from CMV, well established healthcare infrastructure and presence of established market players involved in conducting clinical trials, new product launch, strategic collaboration and expansion. For instance, in May 2016, Hoffman Roche received the United States Food and Drug Administration (FDA) approval of the first cytomegalovirus (CMV) test for use in hematopoietic stem cell transplant recipients. Company introduced the COBAS AmpliPrep/COBAS TaqMan CMV Test and it is available for monitoring CMV infection among transplant patients in US.

Asia Pacific is anticipated to exhibit the fastest growth in the coming years. This owes to the factors such as the rising prevalence of patient population suffering from CMV infection, novel treatment method for the diagnosis, increasing awareness among people related to the virus which will further demand for an effective CMV diagnostic assay. Furthermore, Asia Pacific region is observed to be the fastest growing regional market for cytomegalovirus assay due to increasing patient population suffering from this viral infection. This region is expected to maintain its growth rate in the near future.


  • Abbott
  • Qiagen
  • Abcam plc
  • Danaher Corporation
  • Becton Dickson
  • Biomerieux
  • Eiken Chemicals
  • Elitech Group
  • Fujirebio
  • Affymetrix, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Olympus Corporation
  • Siemens Healthcare
  • Thermo Fisher Scientific, Inc.
  • NeumoDx
  • DiaSorin Molecular


In June 2020, DiaSorin Molecular received CE marking for its product such as Simplexa Congenital CMV Direct kit. The kit enables direct detection of cytomegalovirus DNA in both samples such as saliva swab and urine specimens from infants up to 21 days old. It is the first CE-marked assay that can be run directly from both urine and saliva swab.

In July 2019, NeuMoDx Molecular introduced its product i.e., CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Company offers reagents and consumables for use by customers in developing qualitative and quantitative Laboratory Developed Tests (LDTs) for use with the NeuMoDx systems to detect and amplify DNA and RNA targets.

In January 2019, Lions Eye Institute (LEI), a medical research institute affiliated with the University of Western Australia, discovered a new method to prevent reactivation of CMV in mouse models by injecting them with their own antibodies.

Request For Customization

Request Customization

Check Discount

Request Discount